9-10-15 Merger & Acquisitions/Rumors

9-10-15 Merger & Acquisitions/Rumors

9-10-15 Merger & Acquisitions Rumors

9-10-15 Merger & Acquisitions Rumors…The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday September 10, 2015:

Avon Discusses Stake Sale With Private-Equity Firms — Sources

The Rumor:
Avon Products Inc. (NYSE:AVP) is reportedly in discussions with private-equity firms regarding the sale of a stake, according to sources as reported by the Wall Street Journal on Thursday. The report said Avon is running an auction process for PIPE, Cerberus Capital Management, Platinum Equity and other firms, with bids due next week.

There was no indication of the size of a potential stake.

Avon closed at $4.10 on Thursday, a loss of 9.5%.

Ericsson to Acquire Envivio for $4.10/Share

The Deal:
Ericsson (NASDAQ:ERIC) announced Thursday, an agreement to acquire Envivio (NASDAQ:ENVI) via a tender offer for $4.10 per share in cash, or approximately $125 million. The acquisition is expected to close in Q4 2015.

Envivio closed at $4.06 Thursday, up 113%.

Mindray Receives Revised Non-binding Proposal to Acquire Company for $27/ADS

The Offer:
Mindray Medical International Limited (NYSE:MR) announced Thursday, that the board of directors has received a revised non-binding proposal, dated September 10, 2015, from Executive Chairman Li Xiting, and other

officers, to acquire all of the outstanding shares of Mindray not already owned by the buyers for $27 per ADS. The special committee of the Board is evaluating the revised proposal with financial and legal advisors.

Mindray shares closed at $23.56 Thursday, a loss of 2.5%.

Report of Actelion Approach to ZS Pharma

The Talks:
ZS Pharma, Inc. (NASDAQ:ZSPH) confirmed an earlier Bloomberg report, that it had preliminary discussions with Actelion Ltd. (OTC:ALIOF) regarding a potential deal. ZS Pharma said it regularly and routinely

explores opportunities with various strategic partners and will continue to do so. Actelion also confirmed the preliminary talks regarding a potential deal.

Earlier, it was reported that ZS had cancelled out of the upcoming Morgan Stanley Global Healthcare Unplugged Conference on September 17. A representative of ZS Pharma told Benzinga they were still scheduled to present at that event.

ZS Pharma shares closed at $74.73 Thursday and traded as high as $81.00 after-hours.

Premiere Global Services to be Acquired by Siris Capital for $14.00/Share in Cash

The Deal:
Premiere Global Services, Inc. (NYSE:PGI) announced Thursday, that it has entered into a definitive agreement to be acquired by funds managed or advised by Siris Capital Group for $14.00 per share in cash, a total transaction value of approximately $1 billion.

PGI may solicit alternative acquisition proposals from third parties during a 45-day “go-shop” period, following the date of execution of the merger agreement.